Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...

which will be translated to the clinic to monitor target engagement and modulation. DPTX3496 shows down-regulation of beta catenin-driven gene transcription and Wnt pathway activity in vivo ...

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically ...